The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients
with genetically known disorder of extremely high cholesterol
For additional information please call: 1-800-718-1021
- Diagnosis of Homozygous Familial Hypercholesterolemia
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor)
therapy other than atorvastatin or other concomitant therapy with known lipid
altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
- Subjects taking any drugs known to be associated with an increased risk of myositis
in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could
affect subject safety, preclude evaluationof response, or render unlikely that the
subject would complete the study